|
|
|
|
|
||||||||||||
|
|
|
|
|
|
|
|
Valuation Estimation |
EPS (Current/Estimated)
-0.96/-0.50
|
Enterprise Value
3.10M
|
Balance Sheet |
Book Value Per Share
4.03
|
Cash Flow |
Cash Flow Yield
--
|
Income Statement |
Total Revenue
147.81K
|
Operating Revenue Per Share
0.27
|
Industry Comparison
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
Quotes are at least 15-min delayed:2024/10/31 19:44 EDT
Industry overview quotes are at least 15 minutes delayed
Business Description
|
|||
Sonnet BioTherapeutics Holdings Inc is a clinical-stage biotechnology company. The company has developed FHAB (Fully Human Albumin Binding) technology which is well suited for drug development across a range of human disease areas, including in oncology, autoimmune, pathogenic, inflammatory, and hematological conditions. The firm's pipeline products include SON-080 (low-dose IL-6), SON-1210 (IL15- FHAB-IL12), SON-1010 (IL12-FHAB), and others. |